IHF Awards 2022
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Digital edition
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release
  • White Papers
  • Events
  • Suppliers
  • E-Alert
  • Contact us
  • Subscribe, it’s free!
  • Search
  • Menu Menu
International Hospital

Archive for category: E-News

E-News

Isala Hospital, Netherlands

Isala partners with Aidoc to harness combined potential of radiologists and AI

AI, 25 July 2022/in E-News /by panglobal
Isala Hospital, Netherlands

Isala Hospital, Netherlands

Aidoc, a leading provider of healthcare AI solutions, has signed a strategic agreement with Isala Hospital, one of the largest non-academic medical facilities in the Netherlands. Isala’s implementation of the AI Care platform, which includes three of the ten AI algorithms of Aidoc’s suite of CE-marked and FDA-cleared AI solutions, will empower the hospital to sustain high quality care and scale AI operations as needed.

Research conducted with Aidoc’s solutions shows that when utilized in clinical settings they have had a positive impact on numerous indicators, such as turnaround time, efficiency, and emergency department (ED) throughput.

Under the partnership, Isala will integrate Aidoc’s AI algorithms for triage and notification of intracranial haemorrhage (ICH), pulmonary embolism (PE), and c-spine fractures. Isala is also a member of the Netherland’s seven top clinical hospitals, referred to as mProve, whose mission is to provide patients with better care every day. The inclusion of Aidoc’s AI further consolidates Isala’s position as a front-runner in medical and technical innovation in Europe, while striving to maintain high quality care amid the surging volumes that will continue in the foreseeable future.

“Imaging volumes continue to rise. Therefore, we need a clear plan on how AI technology can support radiologists to manage the increasing workload. AI has proven to offer high value by reducing turnaround time, increasing the radiologists’ confidence and reducing variability of quality,” said Dr Martijn Boomsma, radiologist at Isala and a champion of AI.

“In Aidoc we’ve found the perfect partner, a vendor who is willing to test and demonstrate the performance and is constantly working on improving their algorithms,” Dr Rogier van Dijk, radiologist at Isala and also a champion of AI, added. “At Isala, we have certainly found that value in the ability of Aidoc’s AI platform to complement our radiologists’ strengths. AI offers us a high degree of comfort amid periods of both higher and lower imaging volumes, and especially during night shifts. Beyond radiology, we also observed its ability to make a positive impact on the post-diagnosis patient pathway.”

Aidoc’s AI demonstrates high sensitivity and specificity

In clinical settings, Aidoc’s AI has demonstrated high sensitivity and specificity and the ability to complement radiologist’s strengths. In a study evaluating performance as a complement to  radiologists, Aidoc’s AI showed high sensitivity and negative predictive values while the radiologist demonstrated high specificity and positive predictive value, with 70% of participant radiologists stating that AI could “improve diagnostic comfort”.

In another study, conducted by Unfallkrankenhaus Berlin, researchers showed the potential of Aidoc’s AI and physicians together could increase triaging of positive intracranial haemorrhage cases by 12.2%. Isala evaluated Aidoc’s algorithm for c-spine fractures on a validated database of 2,331 CT scans and showed the potential value of the AI as a concurrent reader by increasing the total number of fractures identified by a radiologist by 13% (ECR 2022 oral presentation).

“We are delighted to have a strategic partner like Isala, who truly sees the value of implementing AI at scale in radiology workflows and the downstream impact it can make,” said Alexander Boehmcker, Aidoc’s VP Europe. “AI is a tool that augments the radiologist and so when paired, the two complement each other and raise diagnostic efficiency. Hospitals like Isala with their visionary leadership are forging a new path, showing how AI will play a pivotal role in the future of hospital care in Europe through rigorous clinical research and perpetually proving AI’s valuable role.”

The Aidoc AI Care platform is home to 16 CE-marked radiology AI solutions – 10 developed in-house and six third-party algorithms – and multidisciplinary team coordination solutions, all driven by the underlying AI OS. Aidoc’s AI Care platform impacts patient care in more than 1,000 medical facilities worldwide, with many located in Europe.

https://interhospi.com/wp-content/uploads/sites/3/2022/07/isala_hospital.jpg 473 709 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-25 10:32:592022-08-03 08:44:48Isala partners with Aidoc to harness combined potential of radiologists and AI

New gene therapy appears to cure haemophilia

, 21 July 2022/in E-News, Featured Articles /by panglobal

gene therapy cure for haemophilia

A Phase I/II multi-centre clinical trial, called B-AMAZE, has found that a single gene therapy injection dramatically reduces the bleeding risk faced by people living with haemophilia B and enabled trial participants to stop their regular blood clotting factor replacement therapy.

The study is published in the July 21, 2022 issue of the New England Journal of Medicine.

Of the 10 male patients selected to take part in the trial, all showed dose-dependent increases in factor IX levels. At a median follow-up of 27.2 months, sustained factor IX activity was observed in all the patients except one.

Haemophilia B is a rare and inherited genetic bleeding disorder caused by low levels of the blood clotting factor IX (FIX) protein.

The gene responsible for making FIX protein is located on the X chromosome, so the severe form of haemophilia B is much more common in men.

Currently, patients with haemophilia B need to inject themselves regularly – usually weekly – with recombinant FIX, a regular replacement therapy to prevent excessive bleeding. Despite advances in treatment, patients may continue to see debilitating joint damage.

The B-AMAZE trial and the related long-term follow up study found that one-time treatment with FLT180a led to sustained production of FIX protein from the liver in nine of ten patients, across four different dose levels. They no longer required weekly injections of FIX protein. They are also all enrolled in the long-term follow up study to assess safety and durability of FIX expression for 15 years.

FLT180a AAV gene therapy

FLT180a (verbrinacogene setparvovec) is a liver-directed adeno-associated virus (AAV) gene therapy. AAV gene therapy works by using a packaging from the proteins found in the outer membrane of the virus, to deliver a functional copy of a gene directly to patient tissues – in this case the liver. Newly synthesised proteins – in this case the FIX protein – are released into the blood. A one-time infusion can achieve long-lasting effects.

Lead author Professor Pratima Chowdary of the Royal Free Hospital, UCL Cancer Institute, said: “Removing the need for haemophilia patients to regularly inject themselves with the missing protein is an important step in improving their quality of life. The long term follow up study will monitor the patients for durability of expression and surveillance for late effects.”

Immunosuppression

Patients in the trial needed to take immune suppressing drugs over several weeks to several months, to prevent their immune systems from rejecting the therapy, and all reported known side effects. While the treatment was generally well tolerated, all patients experienced some form of adverse events, with an abnormal blood clot in one who received the highest FLT180a dose and had the highest levels of FIX protein.

Freeline Therapeutics co-founder Professor Amit Nathwani (UCL Medical Sciences), who co-authored the study, said: “Gene therapy is still a young field that pushes the boundaries of science for people with severe genetic diseases.

“The B-AMAZE long-term data add to the growing body of evidence that gene therapy has the potential to free patients from the challenges of having to adhere to lifelong therapy or could provide treatment where none exists today.”

Pamela Foulds, MD, Chief Medical Officer of Freeline, said: “The B-AMAZE long-term data continue to support our confidence that a single dose of FLT180a could protect people with haemophilia B from bleeding and the need for lifelong FIX replacement through durable expression of FIX at protective levels.”

The Phase I/II trial was sponsored by University College London and funded by Freeline Therapeutics, a clinical-stage biotechnology company developing AAV vector-mediated systemic gene therapies.

A Phase I/II dose-confirmation trial of FLT180a called B-LIEVE to finalize a dose for a Phase 3 pivotal trial is in progress.

https://interhospi.com/wp-content/uploads/sites/3/2022/07/gene.jpg 1701 1701 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-21 10:58:482022-07-21 11:00:52New gene therapy appears to cure haemophilia
Concept image of Paragraf diagnostic handset and test cartridge

UK company to develop world’s first graphene-based rapid in-vitro diagnostic test

graphene, in-vitro tests, 20 July 2022/in E-News, Editors' Picks, Featured Articles /by panglobal
Concept image of Paragraf diagnostic handset and test cartridge

Concept image of Paragraf diagnostic handset and test cartridge — © Paragraph 2022

 

Cambridgeshire, UK-based Paragraf, the first company in the world to deliver a scalable approach to graphene electronic device manufacturing, has announced a plan to develop a new generation of graphene-based, in-vitro diagnostic products that will give results within a few minutes.

With the support of a £550,000 Biomedical Catalyst grant award from Innovate UK, Paragraf initiated a two-year programme to develop a proof-of-concept combined PCT (procalcitonin) and CRP (C-reactive protein) test, on a single panel. On March 1 this year Paragraf raised US$60 million in a Series B financing round.

The company is collaborating with the universities of Liverpool, Manchester and Newcastle, Newcastle upon Tyne Hospitals NHS Foundation Trust and Manchester University NHS Foundation Trust (MFT), on the development.

Clinical study of graphene-based PCT/CRP test

A clinical study of the combined PCT/CRP test will be delivered at MFT’s Diagnostics and Technology Accelerator (DiTA) in mid-2023. DiTA aims to address unmet needs, transform patient care and improve efficiency within the NHS, by facilitating the rapid translation and adoption of new innovations into the healthcare system. The project is expected to be completed by the end of May 2024.

Paul Dark, Professor of Critical Care Medicine at The University of Manchester, and Honorary NHS Consultant at Salford Royal, part of Northern Care Alliance NHS Foundation Trust, said: “We expect to show that our proposed acute inflammatory marker test will have the capability to deliver accurate results for emergency patient care within a few minutes, from a small sample of blood. The accuracy of the test is envisaged to be at least comparable with hospital centralised lab-based immunoassay tests which can take hours to provide results back to emergency services.”

Prof. Dark also leads the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC), Respiratory Non-fungal Infections Programme, which is focused on providing more accurate, rapid diagnosis for patients with severe respiratory infections.

Malcolm Stewart, Paragraf Diagnostics Business Development Director

Malcolm Stewart, Paragraf Diagnostics Business Development Director

Antimicrobial stewardship

Malcolm Stewart, Paragraf Diagnostics Business Development Director, said: “This graphene-based diagnostic test is expected to become the first test in the world to give clinicians the ability to identify patients who need an antibiotic treatment within the space of a regular 15-minute clinic appointment. It encourages antimicrobial stewardship by giving clinicians the insight into when not to prescribe antibiotics as the test result differentiates viral from bacterial infections.”

The role of graphene in the in-vitro test

Commenting on the role of graphene in the test, Stewart explained that graphene enhances the test by having the ability to detect very low levels of the target protein (in this case). “Graphene is one of the most conductive substances ever discovered. The almost immediate electrical conductivity change in the graphene when only picogram levels of the target (in this case PCT) are detected is the difference the graphene makes. Simply put, graphene allows us to detect much lower concentrations of target analytes and in single digit minutes than is conventionally possible – and in a piece of equipment that will be handheld in size.

“We can make the graphene into chip-like devices – called graphene field effect transistors (GFETS) – which allow us to detect multiple analytes on one chip, a technique called multiplexing. This first test we are working on will detect two analytes on one chip – PCT and CRP. In future, tests we will be multiplexing more than six analytes on one chip in the cartridge.

“Graphene is also biocompatible meaning that we can deposit samples without having to pre-prepare them. So in this case, for the PCT/CRP test, we will only require a couple of drops of blood directly into the test cartridge. The reduction in pre-analytical errors is vital for tests like this one being used in critical care areas where time to result is important. Once this test is being used in primary care the lack of pre-preparation of the sample makes the test feasible in a GP surgery or even in a patient’s home,” Stewart explained.

Enitan Carrol, Professor of Paediatric Infectious Diseases at the University of Liverpool, reiterated this point: “This technology reduces the time and complexity of sample preparation which, together with its rapid measurement speed, provides clinicians with accurate results in a timeframe that allows immediate decisions to be made on antimicrobial prescribing. This is especially important for the treatment of children and neonates.”

Paragraf

Paragraf

Manufacturing the graphene in-vitro tests

Explaining the manufacturing process, Stewart said: “As we scale up our business, the graphene will be deposited on to larger wafers – 20 or 30cm diameter – in the future. We then make GFETS from the wafers.

“Our process is called MOCVD (metal oxide chemical vapour deposition) and is not unique to us. But the way we do it and the ingredients we use makes it unique. We can make graphene that is contamination free, because or graphene is directly formed on the wafer rather than transferred from another metal like copper in other graphene manufacturing processes.

“We believe we have a technique that is scalable to millions of chips a year when we are manufacturing our chips on 30cm wafers.”

Plans for series of tests for disease biomarkers

Paragraf plans to deliver a series of high sensitivity, rapid tests for disease biomarkers in areas including cardiovascular disease, oncology, and infectious diseases.

The ambition is to develop a comprehensive suite of tests that could be used in almost any environment or healthcare setting. The tests are designed to provide ultra-fast answers to diagnostic challenges and to create a complete diagnostic toolkit at the point of care.

https://interhospi.com/wp-content/uploads/sites/3/2022/07/Paragraf-Diagnostics-Device-Concept_1.jpg 957 1701 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-20 11:13:022022-07-20 11:14:28UK company to develop world’s first graphene-based rapid in-vitro diagnostic test

£30 million translational partnership will accelerate development of new treat- ments for people with dementia

, 4 July 2022/in E-News /by panglobal

LifeArc and the UK Dementia Research Institute (UK DRI) have launched a new partnership to accelerate development of new diagnostic tests, treatments, and devices from scientific research discoveries to benefit people with dementia. Around 900,000 people in the UK are living with dementia.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/shutterstock_1801707715-scaled.jpg 1707 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 13:37:452022-07-04 17:35:41£30 million translational partnership will accelerate development of new treat- ments for people with dementia

Nerve stimulation promotes resolution of inflammation

, 4 July 2022/in E-News /by panglobal

It is known that the nervous system communicates with the immune system and can regulate inflammation in the body. Now scientists at Karolinska Institutet in Sweden have shown how electrical activation of a specific nerve can promote healing in acute inflammation. The finding, which is published in the journal PNAS, opens new ways to accelerate […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/Peder_Olofsson-scaled.jpg 1706 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 13:34:152022-07-04 13:34:35Nerve stimulation promotes resolution of inflammation

$25 million awarded to inter-national research team to understand genesis of cancer

, 4 July 2022/in E-News /by panglobal

A team of researchers co-led by University of California San Francisco’s Allan Balmain, PhD, FRS, has been selected to receive a $25 million Cancer Grand Challenges award to investigate the very early stages of cancer development. Cancer Grand Challenges is a global funding platform, co-founded by Cancer Research UK (CRUK) and the National Cancer Institute […]

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/shutterstock_433526728-scaled.jpg 1396 2560 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 13:27:392022-07-04 13:27:39$25 million awarded to inter-national research team to understand genesis of cancer

Rapid Profound Hypothermia (Suspended Animation) in Clinical Trials as a new approach to emergency care when CPR fails

, 4 July 2022/in E-News /by panglobal

Emergency Preservation and Resuscitation (EPR), rapid profound hypothermia, is being pursued in clinical trials, as a revolutionary approach to be the next standard of emergency care to save lives when cardiopulmonary resuscitation (CPR) fails.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/EPR.jpg 1128 1396 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 13:23:352022-07-04 13:30:01Rapid Profound Hypothermia (Suspended Animation) in Clinical Trials as a new approach to emergency care when CPR fails

Orion Medical enables 3D printing with thermal radiation heating for precision medicine

, 4 July 2022/in E-News /by panglobal

Orion Medical, founded in Cham, Switzerland in March 2022, is a manufacturing solutions provider for the medical devices industry. The company is closely linked to Orion Additive Manufacturing (Orion AM), an established manufacturer of 3D printing systems for high-performance polymers based in Berlin, Germany.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/orion-med-3d-pring.png 882 1266 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 11:53:322022-07-04 11:53:32Orion Medical enables 3D printing with thermal radiation heating for precision medicine

Ceryx Medical raises £3.8m to bring cardiac device to in-human trials

, 4 July 2022/in E-News /by panglobal

Ceryx Medical, a Cardiff-based healthtech start-up developing bioelectronic technology that can mimic nerve centres to control a range of autonomic or rhythmical processes in the human body, has raised £3.8m in seed funding.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/Ceryx-Cysoni.png 950 920 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 11:50:162022-07-04 11:50:16Ceryx Medical raises £3.8m to bring cardiac device to in-human trials

Capitainer raises $3.3m to meet demand for home-sampling solutions

, 4 July 2022/in E-News /by panglobal

Swedish medtech start-up Capitainer has closed a share issue of SEK34 million (US$3.38 million) to capitalise on growing interest in homesampling with its new qDBS dried blood spot testing system. The investment round, led by Sciety, brought in both existing and new industry specialist investors and several board members and the CEO.

Read more
https://interhospi.com/wp-content/uploads/sites/3/2022/07/capitainer-e1656927779517.png 795 1200 panglobal https://interhospi.com/wp-content/uploads/sites/3/2020/06/Component-6-–-1.png panglobal2022-07-04 11:47:222022-07-04 11:51:10Capitainer raises $3.3m to meet demand for home-sampling solutions
Page 1 of 193123›»
IHF Awards 2022

Latest issue of International Hospital

May / June 2022

25 July 2022

Isala partners with Aidoc to harness combined potential of radiologists and AI

21 July 2022

New gene therapy appears to cure haemophilia

20 July 2022

UK company to develop world’s first graphene-based rapid in-vitro diagnostic test

Digital edition
All articles Archived issues

Free subscription

View more product news

Get our e-alert

The medical devices information portal connecting healthcare professionals to global vendors

Sign up today
  • News
    • Featured Articles
    • Product News
    • E-News
  • Magazine
    • About us
    • Archived issues
    • Free subscriptions
    • Media kit
    • Submit Press Release

Parklaan 54a
5613 BH
Eindhoven
The Netherlands
+31 85064 55 82
info@interhospi.com

PanGlobal Media IS not responsible for any error or omission that might occur in the electronic display of product or company data.

Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

Accept settingsHide notification onlyCookie settings

Cookie and Privacy Settings



How we use cookies

We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.

Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.

We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.

We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.

.

Google Analytics Cookies

These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.

If you do not want us to track your visit to our site, you can disable this in your browser here:

.

Other external services

We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page

Google Webfont Settings:

Google Maps Settings:

Google reCaptcha settings:

Vimeo and Youtube videos embedding:

.

Privacy Beleid

U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.

Privacy policy
Accept settingsHide notification only